FDA Approves First Vaccine for Highly Contagious Lung Infection

May 3, 2023 by Dan McCue
FDA Approves First Vaccine for Highly Contagious Lung Infection
S team of scientists working in an R&D laboratory at GlaxoSmithKline's Stevenage, UK site. (GlaxoSmithKline photo)

WASHINGTON — The Food and Drug Administration on Wednesday licensed the first-ever vaccine for respiratory syncytial virus, or RSV, a highly contagious virus that is a common cause of lower respiratory tract disease in older adults.

The vaccine, Arexvy, was developed by GlaxoSmithKline Biologicals and has been approved for adults ages 60 and older.

“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Dr. Peter Marks, Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, in a written statement. 

“Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States,” he added.


RSV is a virus that typically circulates seasonally, starting in the fall and peaking in the winter. All age groups are vulnerable to the infections it causes to the lungs and breathing passages, but it can be particularly serious for older adults, in whom it can cause life-threatening pneumonia and bronchiolitis (swelling of the small airway passages in the lungs). 

According to the Centers for Disease Control and Prevention, each year in the U.S., RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 and older. 

The safety and effectiveness of Arexvy is based on the FDA’s analysis of data from an ongoing, randomized, placebo-controlled clinical study conducted in the U.S. and internationally in individuals 60 years of age and older. 

The main clinical study of Arexvy was designed to assess the safety and effectiveness of a single dose administered to individuals 60 years of age and older. 

Participants will remain in the study through three RSV seasons to assess the duration of effectiveness and the safety and effectiveness of repeat vaccination. 

Data for a single dose of Arexvy from the first RSV season of the study were available for the FDA’s analysis.  


In this study, approximately 12,500 participants received Arexvy and 12,500 participants received a placebo. 

Among the participants who received Arexvy and the participants who received a placebo, the vaccine significantly reduced the risk of developing RSV-associated LRTD by 82.6% and reduced the risk of developing severe RSV-associated LRTD by 94.1%.

Among a subset of these clinical trial participants, the most commonly reported side effects by individuals who received Arexvy were injection site pain, fatigue, muscle pain, headache and joint stiffness/pain. 

Among all clinical trial participants, atrial fibrillation within 30 days of vaccination was reported in 10 participants who received Arexvy and four participants who received placebo. 

In two other studies, approximately 2,500 participants 60 years of age and older received Arexvy. 

In one of these studies, in which some participants received Arexvy concomitantly with an FDA-approved influenza vaccine, two participants developed acute disseminated encephalomyelitis, a rare type of inflammation that affects the brain and spinal cord, seven and 22 days, respectively, after receiving Arexvy and the influenza vaccine. 

One of the participants who developed ADEM died. 

In the other study, one participant developed Guillain-Barré syndrome (a rare disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) nine days after receiving Arexvy.


The FDA is requiring the company to conduct a postmarketing study to assess the signals of serious risks for Guillain-Barré syndrome and ADEM. In addition, although not an FDA requirement, GlaxoSmithKline has committed to assess atrial fibrillation in the postmarketing study.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • Food and Drug Administration
  • GlaxoSmithKLine
  • lung infection
  • Respiratory syncytial virus
  • RSV
  • In The News

    Health

    Voting

    Health

    June 9, 2023
    by Carter Schaffer
    President’s Council on Sports, Fitness and Nutrition to Hold Public Meeting

    WASHINGTON — The President’s Council on Sports, Fitness and Nutrition will hold its first public meeting in three years on... Read More

    WASHINGTON — The President’s Council on Sports, Fitness and Nutrition will hold its first public meeting in three years on June 27, with members expected to revise old priorities and set new ones in the wake of the coronavirus pandemic. The panel’s last meeting was held... Read More

    June 8, 2023
    by Dan McCue
    Smoke Continues to Be a Problem for DC Region

    WASHINGTON — The region’s first air quality emergency this year continued on Thursday and is expected to linger into Friday... Read More

    WASHINGTON — The region’s first air quality emergency this year continued on Thursday and is expected to linger into Friday as the wildfires causing the unhealthy air here continue to rage in parts of Canada. At the White House on Wednesday, spokeswoman Karine Jean-Pierre said President... Read More

    Biden Unveils LGBTQ+ Initiatives Ahead of Pride Month Celebration

    WASHINGTON (AP) — President Joe Biden has invited thousands of LGBTQ+ individuals to celebrate Pride Month on Thursday in a high-profile show... Read More

    WASHINGTON (AP) — President Joe Biden has invited thousands of LGBTQ+ individuals to celebrate Pride Month on Thursday in a high-profile show of support at a time when the community feels under attack like never before and the White House has little recourse to beat back a flood... Read More

    June 7, 2023
    by Dan McCue
    Think Tank Weighs In on Medicare Payments for Ambulatory Services

    WASHINGTON — As Congress considers proposals that would eliminate existing differences in Medicare payments for ambulatory services, a think tank... Read More

    WASHINGTON — As Congress considers proposals that would eliminate existing differences in Medicare payments for ambulatory services, a think tank is warning lawmakers to be on the lookout for unintended consequences. In a new paper published by the American Enterprise Institute, a center-right public policy think... Read More

    June 7, 2023
    by Dan McCue
    Large Number of Rural Transgender Adults Feel They Lack Family Support

    MINNEAPOLIS, Minn. — Transgender adults living in rural communities are far less likely to feel they get the familial support... Read More

    MINNEAPOLIS, Minn. — Transgender adults living in rural communities are far less likely to feel they get the familial support they need than those living in urban settings or so-called cisgender adults, those who identify with the sex registered for them at birth, a new university... Read More

    June 7, 2023
    by Dan McCue
    Break Out Those Face Masks Again as Smoke Blankets US Cities

    WASHINGTON — Weather and health officials are advising those living in some of the most heavily populated communities in the... Read More

    WASHINGTON — Weather and health officials are advising those living in some of the most heavily populated communities in the U.S. to consider donning face masks and varying their daily routines in light of a blanket of smoke rolling over most of the eastern half of... Read More

    News From The Well
    scroll top